Immunotherapy for acute lymphoblastic leukemia: from famine to feast
Author:
Affiliation:
1. Department of Pediatrics and
2. Department of Medicine, Stanford University, Stanford, CA
Publisher
American Society of Hematology
Subject
Hematology
Link
http://ashpublications.org/bloodadvances/article-pdf/1/3/265/877835/advances000034.pdf
Reference31 articles.
1. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia;Kantarjian;N Engl J Med,2016
2. Bone marrow transplantation for leukaemia: a lame stalking horse for use of high-technology medical care;Magrath;Lancet,1995
3. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial;Lee;Lancet,2015
4. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab;Schlegel;Haematologica,2014
5. Initial results from a phase 2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia [abstract];Gore;Blood,2014
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Role of peripheral blood MRD and 18F-FDG PET in the post-CAR relapse setting: a case study of discordant peripheral blood and bone marrow MRD;Journal for ImmunoTherapy of Cancer;2023-02
2. CD4 CAR-T cells targeting CD19 play a key role in exacerbating cytokine release syndrome, while maintaining long-term responses;Journal for ImmunoTherapy of Cancer;2023-01
3. Development of CAR T Cell Therapy in Children—A Comprehensive Overview;Journal of Clinical Medicine;2022-04-12
4. Synapse topology and downmodulation events determine the functional outcome of anti-CD19 T cell-redirecting strategies;OncoImmunology;2022-03-23
5. Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL;Journal of Clinical Oncology;2021-11-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3